The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy - PubMed (original) (raw)
Clinical Trial
The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy
A Y Kinney et al. Cancer. 1997.
Abstract
Background: Sialyl-Tn (STn) represents an aberrantly glycosylated mucin epitope that is expressed in breast carcinoma and other adenocarcinomas and is an important factor in the development of novel immunotherapeutic approaches. The primary aim of the current study was to investigate the influence of STn expression on the prognoses of patients with breast carcinoma.
Methods: A cohort of 207 women diagnosed with invasive breast carcinoma who were treated with anthracycline-containing adjuvant chemotherapy and were enrolled in a randomized clinical trial were studied. Expression of STn was determined by an immunohistochemical procedure in which the B72.3 monoclonal antibody was used. Kaplan-Meier and Cox proportional regression survival analyses were used to compare low STn and high STn patients.
Results: Forty-eight (23%) of the 207 specimens demonstrated high STn staining (>25% cells were immunoreactive). During a median follow-up of 5 years, high STn patients had worse disease free survival than low STn patients (55% vs. 74%, respectively; P = 0.03). High STn expression was significantly associated with age (P = 0.04) but not with other conventional prognostic markers. In multivariate analysis using the Cox regression model, high STn emerged as an independent prognostic indicator for disease free survival (hazard ratio [HR], 2.02; 95% confidence interval [CI], 1.09-3.73) and for overall survival (HR, 2.16; 95% CI, 0.95-4.92).
Conclusions: The results of this study suggest that STn may be a valuable marker for identifying women at high risk of developing recurrent breast carcinoma who may be candidates for trials investigating new therapies in combination with standard adjuvant therapy.
Similar articles
- Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H. Kurebayashi J, et al. Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8. Breast Cancer. 2015. PMID: 23749689 - Immunohistochemical expression of T, Tn and sialyl-Tn antigens and clinical outcome in human breast carcinoma.
Imai J, Ghazizadeh M, Naito Z, Asano G. Imai J, et al. Anticancer Res. 2001 Mar-Apr;21(2B):1327-34. Anticancer Res. 2001. PMID: 11396208 - Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Schramm A, Schochter F, Friedl TWP, de Gregorio N, Andergassen U, Alunni-Fabbroni M, Trapp E, Jaeger B, Heinrich G, Camara O, Decker T, Ober A, Mahner S, Fehm TN, Pantel K, Fasching PA, Schneeweiss A, Janni W, Rack BK; SUCCESS Study Group. Schramm A, et al. Clin Breast Cancer. 2017 Jul;17(4):279-285. doi: 10.1016/j.clbc.2016.11.008. Epub 2017 Jan 10. Clin Breast Cancer. 2017. PMID: 28190761 Clinical Trial. - Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.
Bozovic-Spasojevic I, Ameye L, Paesmans M, Larsimont D, Di Leo A, Dolci S, Piccart M, de Azambuja E, Loi S. Bozovic-Spasojevic I, et al. Breast. 2014 Aug;23(4):473-81. doi: 10.1016/j.breast.2014.03.012. Epub 2014 Apr 24. Breast. 2014. PMID: 24768477 - Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer.
Miles D, Papazisis K. Miles D, et al. Clin Breast Cancer. 2003 Feb;3 Suppl 4:S134-8. doi: 10.3816/cbc.2003.s.002. Clin Breast Cancer. 2003. PMID: 12620150 Review.
Cited by
- Regulation of the metastatic cell phenotype by sialylated glycans.
Schultz MJ, Swindall AF, Bellis SL. Schultz MJ, et al. Cancer Metastasis Rev. 2012 Dec;31(3-4):501-18. doi: 10.1007/s10555-012-9359-7. Cancer Metastasis Rev. 2012. PMID: 22699311 Free PMC article. Review. - Recent Progress on Therapeutic Vaccines for Breast Cancer.
Zhang L, Zhou X, Sha H, Xie L, Liu B. Zhang L, et al. Front Oncol. 2022 Jun 6;12:905832. doi: 10.3389/fonc.2022.905832. eCollection 2022. Front Oncol. 2022. PMID: 35734599 Free PMC article. Review. - Mucin-type sialyl-Tn antigen is associated with PD-L1 expression and predicts poor clinical prognosis in breast cancer.
Xu F, Zhao H, Li J, Jiang H. Xu F, et al. Gland Surg. 2021 Jul;10(7):2159-2169. doi: 10.21037/gs-21-83. Gland Surg. 2021. PMID: 34422587 Free PMC article. - Clinical Data on Immunotherapy in Breast Cancer.
Radosa JC, Stotz L, Müller C, Kaya AC, Solomayer EF, Radosa MP. Radosa JC, et al. Breast Care (Basel). 2020 Oct;15(5):450-469. doi: 10.1159/000511788. Epub 2020 Oct 13. Breast Care (Basel). 2020. PMID: 33223989 Free PMC article. Review. - Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies.
Barbera-Guillem E, May KF Jr, Nyhus JK, Nelson MB. Barbera-Guillem E, et al. Neoplasia. 1999 Nov;1(5):453-60. doi: 10.1038/sj.neo.7900054. Neoplasia. 1999. PMID: 10933061 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Other Literature Sources
Medical